Blog

Company News

Industry Trends

Laws Regulations

All Categories >

16

2023-08

Anti-FMC63 Antibody | Precise Support for CD19 CAR Cell Therapy Research

CD19 is currently the most widely used target in CAR-T cell therapy, and numerous studies have demonstrated that CD19 is an effective and safe target for the treatment of B-cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL), and B-cell lymphomas. FMC63 is a murine monoclonal antibody that targets human CD19. To date, the majority of reported CAR-T clinical trials have constructed CAR-T cells based on the FMC63 antibody sequence, including the two FDA-approved anti-CD19 CAR-T cell therapies, Kymriah and Yescarta. According to the “Research Guidelines on Quality Control Testing and Nonclinical Considerations for CAR-T Cell Therapy Products” issued by the National Institute for Food and Drug Control in 2018, flow cytometry should be used to assess CAR transduction positivity, with preference given to antigen-specific proteins or anti-idiotypic antibodies that exhibit superior specificity for the antigen-binding site.

2023-08-16

He Yousheng

16

2023-08

Hycells Launches a Groundbreaking Product | γδ T (Vγ9Vδ2-T) Cell Expansion Kit

γδ T cells represent an emerging frontier in tumor immunology; like αβ T cells, they can exert cytotoxic effector functions (ADCC) and produce pro-inflammatory cytokines. The key distinction is that γδ T cells recognize tumor antigens in an MHC-unrestricted manner, endowing them with the characteristics of a universal cell therapy product. The TCRγδ on the surface of γδ T cells does not require binding to MHC molecules or antigen presentation by antigen-presenting cells (APCs); instead, it can directly recognize and bind antigenic molecules. However, the repertoire of TCRγδ variants is limited and lacks diversity, resulting in a relatively narrow antigen-recognition spectrum for γδ T cells. γδ T cells in different tissues express distinct TCRγδ receptors and recognize antigens with varying properties, whereas γδ T cells within the same tissue typically express the same TCRγδ and recognize antigens of the same type.

2023-08-16

He Yousheng

03

2023-08

Little “Life” Makes Sense (II) | Double Agent—Treg

Regulatory T cells (also known as Tregs) are a subset of T cells that play a critical role in modulating or suppressing the activity of other immune cells. Tregs regulate immune responses to both self-antigens and foreign antigens, thereby helping to prevent autoimmune diseases. Based on their developmental origin and functional characteristics, Tregs can be classified into two main subsets: natural regulatory T cells (nTregs) and inducible regulatory T cells (iTregs). Both subsets broadly express the transcription factor Foxp3. nTregs develop naturally in the thymus, where their suppressive function is mediated through direct cell–cell contact, whereas iTregs arise from naïve peripheral T cells that are induced by microenvironmental signals in the tumor microenvironment, including tumor-associated antigens, cytokines such as TGF-β, and other soluble factors.

2023-08-03

He Yousheng

03

2023-08

“Little ‘Life’ Makes Sense (I)” | A Brief Discussion of NK Cells

Natural killer (NK) cells are potent effector cells of the innate immune system, serving as the first line of defense against diseases, including malignant tumors, and representing the third major class of lymphocytes alongside T cells and B cells. NK cells originate from hematopoietic stem cells in the bone marrow, account for approximately 15% of all immune cells in the blood, and are predominantly found in peripheral blood, the liver, and the spleen. In humans, the defining characteristic of NK cells is a CD3−CD16+/CD56+ lymphocyte population.

2023-08-03

He Yousheng

21

2023-07

Exhibition Recap | Hycells Biotechnology Launches Multiple New Products at IBI EXPO 2023

Biologics innovation drugs have become a fiercely contested frontier in the biopharmaceutical industry, and a comprehensive, mature supply chain is indispensable for the sector’s development. With global supply chains still vulnerable, domestic substitution in CDMO services and supply-chain components has emerged as a new perspective on translating research outcomes into commercial value for many companies in this space. Against this pharmaceutical landscape, the IBI EXPO 2023 International Biologics Innovation Drug Industry Conference was launched, taking place from July 13 to 15 at the Shanghai Multinational Procurement Exhibition Center. As a pioneer in domestic substitution, Heyou Bio was also invited to participate in this event.

2023-07-21

He Yousheng

21

2023-07

Exhibition Invitation | Hycells Biotechnology Invites You to Attend IBI EXPO 2023, the International Bio-Innovative Drug Industry Conference

Shanghai Hycells Biotechnology Co., Ltd. was founded in 2021. With many years of deep expertise in cell therapy and gene therapy, the company is an innovative biotech firm primarily focused on delivering products and services in these fields. Its core business encompasses the collection and application of human immune cells, along with supporting biological reagents. Grounded in high-standard clinical sample collection and testing services, the company integrates biological sample management with translational medicine research to provide specialized in vitro and in vivo drug evaluation models and services for the development of innovative pharmaceuticals. Adhering to the core values of talent-driven excellence, quality-first principles, and innovation as the foundation, the company leverages technological innovation to continuously enhance the quality of clinical biological sample collection, processing, and application, thereby setting new industry benchmarks for domestic substitution and laying a solid foundation for the advancement and global competitiveness of China’s innovative drugs.

2023-07-21

He Yousheng
< 1...161718...24 >